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mediate [9–12]. Therefore, the substrate specificity of
fXa is altered in the presence of fVa and phospholipids.
Fluorescent reporter groups placed strategically in
the active site of fXa have provided valuable information
about conformational changes that presumably occur
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Summary in such studies (see [16] and the references therein).
These studies suggest that fVa stoichiometrically binds
The multiprotein complex of factor Xa, factor Va, and to fXa in a calcium-dependent fashion in the presence of
prothrombin efficiently generates the blood-clotting negatively charged phospholipids [13, 15, 17]. However,
agent, thrombin. Here, the formation of the factor this affinity is as much as 1000-fold weaker in the ab-
Xa•prothrombin complex and the effects of factor Va sence of phospholipid surfaces. fVa may enhance the
on this complex were examined using a photoactivable activity of fXa in the prothrombinase complex by several
thiol-specific fluorescent probe (LWB), which was syn- mechanisms. fVa increases the lipid binding affinity of
thesized and incorporated into the active site of factor fXa and also has a direct effect on the active site of fXa,
Xa. The use of fluorescent LWB illustrated that factor altering the active site conformation [16]. fVa also binds
Xa has an increased affinity for prothrombin in the to and alters the conformation of the substrate [18].
presence of factor Va. Further exposure of these com- Studies using fluorescence resonance energy transfer
ponents to UV light resulted in a specific photocross- (FRET) between the donor dyes positioned in the active
linking of LWB-factor Xa to prothrombin, suggesting site of fXa and acceptors on the membrane surface ob-
a physical association between these proteins. These served substantial differences in the extent of energy
data demonstrate that LWB can successfully function transfer between fXa•fVa•phospholipid complexes com-
both as a spectroscopic probe and as a photocross- pared with fXa•phospholipid complexes [15]. The alter-
linking reagent for studying protein-protein interac- ation in energy transfer translates to a reorientation of
tions. the active site of the enzyme above the membrane sur-
face in the presence of the cofactor protein. Thus, the
Introduction biophysical studies are in agreement with the kinetic
data and additionally provide a structural explanation for
The activation of zymogen prothrombin to its active the 13,000-fold fVa-dependent increase in fXa activity.
form, thrombin, is an essential step in blood coagulation Although the kinetics of prothrombin activation by
[1]. This activation is accomplished at a physiologically fXa are well characterized, the binding of factor Xa to
relevant rate by the prothrombinase complex, a macro- prothrombin is less well characterized. This may be
molecular association of the serine protease factor Xa partly due to a lack of probes that are sensitive to the
(fXa) with its cognate cofactor, factor Va (fVa), and sub-
interaction between the two proteins, or it may be due
strate, prothrombin, on negatively charged phospholipid
to problems encountered in the preparation of an en-
surfaces (Figure 1) [2–5].
zyme that does not hydrolyze its substrate upon interac-
The prothrombinase has been well characterized and
tion. Recently, several reports suggest that enzyme-is an archetype for other blood clotting complexes,
substrate interactions involving vitamin K-dependentpartly because it directly leads to the generation of
serine proteases may be dictated by exosite interactionsthrombin, a multifunctional enzyme that can lead to a
distal to the active site rather than by the active siteprocoagulant, anticoagulant, and/or antifibrinolytic re-
[19–21]. These results suggest that active site-specificsponses depending on the local environment [6, 7]. De-
probes could be used to investigate the prothrombinasetailed kinetic analyses by several groups show that fVa,
complex from a “prothrombin perspective”. This ap-the nonenzymatic cofactor in the prothrombinase com-
proach would enable the direct measurement of theplex, enhances the ability of fXa to activate prothrombin
binding interaction between fXai and prothrombin andby over 13,000-fold [3–5]. In this reaction, fVa functions
would give insights into the effect of fVa on this inter-both as a K-type and a V-type effector, decreasing the
action.KM and increasing the kcat, respectively [8]. Additionally,
To detect the formation of the fXa•prothrombin com-in the presence of fVa and phospholipid, prothrombin
plex, we have taken a two-pronged approach usingactivation occurs exclusively via a meizothrombin inter-
steady-state fluorescence spectroscopy and a photo-mediate; whereas, in the absence of these two compo-
crosslinking technique. To do this efficiently, we have syn-nents, the activation proceeds via a prethrombin 2 inter-
thesized a reagent we call “LWB”. LWB features three
functional groups: a fluorescent fluorescein reporter; a4 Correspondence: dawson@scripps.edu (P.E.D.), jgriffin@scripps.
edu (J.H.G.) photoactivable benzophenone group; and a thiol-reactive
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Figure 1. A Schematic Representation of the Prothrombinase
Complex
A schematic representation of the prothrombinase complex is
shown. Factor Xa (fXa), the serine protease, is shown in yellow.
Its cofactor, factor Va (fVa), is depicted in red, and the substrate,
prothrombin (fII), is depicted in blue. Also shown are two cleavage Figure 3. Active Site-Directed Labeling of Factor Xa with LWB
products of prothrombin, an intermediate meizothrombin (mIIa) and
A schematic representation of the active site-directed labeling ofthe product -thrombin. The membrane surface is shown in green.
fXa with LWB (magenta). Enz (in green) represents factor Xa or any
other serine protease. Phe-Phe-Arg represents the phenylalanine,
phenylalanine, and arginine residues in the tripeptide chlorometh-
bromoacetyl group, aiming to combine the advantages of ylketone.
fluorescence and photocrosslinking techniques.
Results agreement with the calculated average isotopic mass
of 877.7 amu. The compound was lyophilized and was
stored in the dark at 20C for future use.Synthesis of LWB and Active Site-Directed
Labeling of Factor Xa with LWB To prepare human LWB-FFR-fXai, we have utilized an
approach similar to one proposed by Bock (Figure 3)LWB (Figure 2) was synthesized by manual SPPS proce-
dure for Boc-chemistry [22]. Prior to cleavage from the [23]. fXa was inactivated by the modified inhibitor
N-([acetylmercapto] acetyl)-(D-phenylalanyl)-phenylal-resin, the Fmoc group on the -amino group of the Lys
residue was removed and the Lys residue was bromoacet- anyl-arginyl-chloromethylketone. After purification of
the inhibited enzyme from the excess unreacted re-ylated. The cleaved reagent was then purified by HPLC
and was characterized by electrospray/ionization mass agents using conventional biochemical techniques, the
inhibited reagent was treated with an excess of LWBspectrometry (ESI-MS). LWB eluted as a single sharp
peak at44% acetonitrile. The molecular weight of LWB in the presence of a nucleophile such as NH2OH. The
resulting free thiol generated in situ on the inhibitedwas determined by ESI-MS to be 877.4  0.5 amu, in
Figure 2. Chemical Structure and a Sche-
matic Representation of LWB
The structure of LWB is shown as a chemical
structure and a schematic, respectively.
(A) The fluorophore, fluorescein (shown in
orange).
(B) The photocrosslinker, benzophenone, is
shown in blue.
(C) The thiol reactive moiety, a bromoacetyl
group, is shown in green.
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Figure 4. SDS-PAGE Analysis of Active Site-Specific Labeling Pro-
cedure
(A) AMA-FFR-fXai (11 M) in 50 mM HEPES (pH 7.4), 150 mM NaCl,
1 mM EDTA was incubated with LWB in the presence of 0.1 M
NH2OH for 1 hr at 25C. The reaction mixture was then purified
according to procedures detailed in the Experimental Procedures.
Purified product (20 l) was analyzed using nonreduced SDS-PAGE
on a 4%–12% gradient gel. The fluorescence of LWB-FFR-fXai was
visualized using an UV illuminator prestaining with Coomassie blue
(lanes 2 and 3). Lane 1 contains samples from a mock labeling
reaction of AMA-FFR-fXai with LWB in the absence of NH2OH.
(B) Figure 4A stained using Coomassie blue G250. Figure 5. PC/PS Dependence of LWB-FFR-fXai Fluorescence
LWB-FFR-fXai (initially 200 nM in cuvette) in 50 mM HEPES (pH 7.4),
150 mM NaCl, 2 mM CaCl2 was titrated with PC/PS vesicles, and
enzyme reacts site specifically with the bromoacetyl the steady-state anisotropy of the fluorescein moiety in LWB-FFR-
fXai was monitored at 490 nm excitation and 520 nm emissiongroup on LWB to generate LWB-FFR-fXai. LWB-FFR-
(closed circles). At the end of the titration, 5 mM EDTA (final) wasfXai was purified from the excess reagents and was
added to the cuvette (open circle).stored in the dark at 80C for future use.
Characterization of LWB-FFR-fXai
mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl2 were 500The dye-to-protein ratio in LWB-FFR-fXai averaged 0.75,
and 525 nm, respectively. The steady-state anisotropy ofassuming a molar extinction coefficient of 84,000 M1
the free LWB-FFR-fXai in the same buffer averagedcm1 for the fluorescein moiety in LWB [23]. Figure 4A
0.205  0.001. The quenching constant (Ksv) for NaI(lanes 2 and 3) shows a nonreduced SDS-PAGE analysis
quenching at room temperature was determined to beof the purified LWB-FFR-fXai on a 4%–12% gradient gel.
8.79 mM for LWB-FFR-fXai and 8.71 mM for free fluores-The fluorescence of LWB-FFR-fXai was visualized using
cein, indicating that the fluorescein probe in the labeleda UV illuminator. Staining with Coomassie blue was used
fXa was highly accessible for collisional quenching.to visualize protein bands (Figure 4B). The nonreduced
LWB-FFR-fXai migrated as a fluorescent band corre-
LWB-FFR-fXai Binding to Phospholipid Vesiclessponding to 45.7 kDa, the molecular weight of unlabeled
fXa binds negatively charged phospholipid vesicles infXa. The detection of intense fluorescence with the pro-
a calcium-dependent fashion via the Gla domain [13,tein band indicates that fluorescein was covalently
15, 24–26]. Upon the addition of phosphatidylcholine/attached to fXa. A mock labeling was performed either
phosphatidylserine (PC/PS) vesicles, the anisotropy ofin the absence of the nucleophile, NH2OH (lane 1, Figure
free LWB-FFR-fXai increased from 0.205  0.001 to4A), or in the absence of the Bock inhibitor (data not
0.237  0.002. Figure 5 illustrates the PC/PS depen-shown). Lane 1 in Figure 4A shows the absence of a
dence of LWB-FFR-fXai anisotropy. At the end of thefluorescent band comigrating with the stained protein
PC/PS titration, EDTA added to the samples dissociatedband (lane 1, Figure 4B) when the AMA-FFR-fXai was
the membrane-bound LWB-FFR-fXai. The emission in-reacted with LWB in the absence of the hydroxylamine.
tensity of the fluorescein moiety in LWB-FFR-fXai wasSimilarly, an absence of conjugation between fXa and
also sensitive to the presence of PC/PS vesicles. WhenLWB was observed without the Bock inhibitor (data not
LWB-FFR-fXai was titrated with PC/PS, the emissionshown). Thus, LWB conjugated to the active site of fXa
intensity decreased by 33% and reached a minimumonly in the presence of the hydroxylamine-treated Bock
at40 M PC/PS. Upon the addition of EDTA to reversereagent.
membrane binding, the emission intensity increased andUsing the same labeling procedure described in the
reached a value similar to that of free LWB-FFR-fXai.Experimental Procedures, LWB was successfully used
Thus, both the anisotropy and the emission intensity ofto label two other serine proteases, thrombin and factor
LWB-FFR-fXai were sensitive to binding to PC/PS.VIIa (data not shown). The labeling of these three serine
proteases demonstrated that the labeling procedure
was nonspecific for trypsin-like serine proteases. Cofactor Dependence of LWB-FFR-fXai
Fluorescence
fVa forms a complex with PC/PS-bound fXa [16]. ToSpectral Properties
In the fluorescence studies, corrected wavelength max- investigate the cofactor dependence of LWB-FFR-fXai
fluorescence, samples of PC/PS-bound LWB-FFR-fXaiima for excitation and emission of LWB-FFR-fXai in 50
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thrombin, a dose-dependent increase in fluorescein an-
isotropy was observed (Figure 7A). This prothrombin-
dependent change in anisotropy reached a maximum
value of 0.266 at 1400 nM prothrombin. Similarly, the
emission intensity of the LWB-FFR-fXai•PC/PS complex
also showed a prothrombin-dependent increase of32%
before reaching a plateau (data not shown). These hyper-
bolic titration curves suggest the formation of a LWB-FFR-
fXai•PC/PS•prothrombin ternary complex.
Figure 7B shows the effects of fVa on fXa-prothrombin
interactions. First, PC/PS vesicles were titrated into
LWB-FFR-fXai until the PC/PS-dependent change in
LWB-FFR-fXai anisotropy reached a plateau. An excess
of PC/PS was added so that sufficient vesicles were
present to bind an excess of fVa and prothrombin. Sec-
ond, fVa was added to the LWB-FFR-fXai•PC/PS solu-
tion until the fVa-dependent change in LWB-FFR-fXai
anisotropy reached a plateau. Finally, prothrombin was
titrated into the LWB-FFR-fXai•PC/PS•fVa ternary com-
plex. A further prothrombin-induced increase in LWB-
Figure 6. Factor Va Dependence of LWB-FFR-fXai Fluorescence FFR-fXai anisotropy that reached a plateau at 150 nM
LWB-FFR-fXai (initially 200 nM in cuvette) in 50 mM HEPES (pH 7.4), prothrombin was observed. At the end of the prothrom-
150 mM NaCl, 2 mM CaCl2 was titrated with PC/PS vesicles. The bin titration, the addition of EDTA reversed the fluores-
anisotropy value increased from a value of 0.205 (for free LWB-FFR- cein anisotropy to a value similar to that of LWB-FFR-
fXai) to a value of 0.237 upon the addition of 80 M PC/PS. At this fXai free in solution, suggesting that all changes causedpoint, factor Va was titrated into the cuvette (closed circles). In a
by phospholipid vesicles, fVa, and prothrombin wereparallel titration, the LWB-FFR-fXai•PC/PS complex was titrated
calcium dependent. These data suggest that the inactivewith protein C (open circles).
LWB-FFR-fXai forms a quaternary complex with pro-
thrombin in the presence of fVa, negatively charged
were prepared with sufficient vesicles to bind both fXa phospholipids, and calcium ions.
and an excess of fVa. When the LWB-FFR-fXai•PC/PS
complex was titrated with factor Va, the fluorescein an-
isotropy increased by 30% before reaching a plateau LWB as a Photoactivable Crosslinker
The interaction of fXa with prothrombin was also moni-value (Figure 6). Similarly, a 50% increase in emission
intensity of the probe was observed upon the addition tored using photocrosslinking. LWB-FFR-fXai was incu-
bated for 5 min at room temperature with prothrombinof fVa (data not shown). An excess of EDTA was added
at the end of the factor Va titration to test if the spectral and excess PC/PS in the presence of calcium ions be-
fore being irradiated with UV light for 2 min. After expo-changes were calcium ion dependent because the
fXa•fVa•PC/PS complex dissociates in the absence of sure to UV light, the reaction mixture was analyzed using
SDS-PAGE and immunoblotting with anti-fX antibodiescalcium ions [14]. The addition of EDTA changed the
anisotropy and emission intensity of the LWB-FFR- (Figure 8A). Lane 1 (Figure 8A), which contained the
complete reaction mixture, shows the appearance of afXai•PC/PS•fVa complex to values equal to those of
free LWB-FFR-fXai, indicating that calcium ions were crosslinked product (indicated by an arrow) migrating
with an apparent molecular weight of 114.5 kDa. Thisrequired for the formation of this ternary complex. Pro-
tein C is the zymogen form of the anticoagulant serine molecular weight corresponds to the theoretical mass
of a fXa-prothrombin-crosslinked protein band. Approx-protease-activated protein C (reviewed in [27]). To test
the specificity of fVa-induced spectral changes in LWB- imately 28% of the total fXa seem to crosslink to pro-
thrombin according to estimates using Un-Scan-It (5.1)FFR-fXai, protein C, which binds negatively charged
phospholipid vesicles but not fXa [27], was added to a software (Silk Scientific). The controls in lanes 2 and 3,
containing samples lacking prothrombin or LWB-FFR-preformed LWB-FFR-fXai•PC/PS complex. No changes
in the anisotropy (Figure 6) or emission intensity (data fXai, respectively, showed that both prothrombin and
LWB-FFR-fXai were necessary to generate the 114.5-not shown) of LWB-FFR-fXai were observed, implying
that the spectral changes in the LWB-FFR-fXai•PC/PS kDa band.
To examine the specificity of photocrosslinking, pro-complex caused by fVa are due to specific interactions
between fXa and fVa. tein C was incubated with the LWB-FFR-fXai•PC/PS
complex. After exposure to UV light, the reaction mixture
was analyzed on immunoblots using a monoclonal anti-Substrate Dependence of LWB-FFR-fXai
Fluorescence human protein C (C-3) antibody (Figure 8B). No high-
molecular weight adduct of protein C with fXa was ob-The effect of the physiological substrate of fXa, prothrom-
bin (reviewed in [1, 2]), on LWB-FFR-fXai fluorescence served (lane 3 compared with lanes 2 and 4), suggesting
that, although protein C was present on PC/PS vesicleswas investigated. When PC/PS-bound LWB-FFR-fXai was
prepared with sufficient vesicles to bind both labeled fXa with LWB-FFR-fXai, it did not crosslink to fXa. Therefore,
these experiments suggest that the photocrosslinks thatand an excess of prothrombin and was titrated with pro-
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Figure 7. Prothrombin Dependence of LWB-FFR-fXai Fluorescence
(A) LWB-FFR-fXai (initially 200 nM in cuvette) in 50 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl2 was titrated with PC/PS vesicles. The
anisotropy value increased from a value of 0.205 (for free LWB-FFR-fXai) to a value of 0.237 upon the addition of 80 M PC/PS. At this point,
prothrombin was titrated into the cuvette (closed circles).
(B) LWB-FFR-fXai (initially 200 nM in cuvette) in 50 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl2 was titrated with 80 M PC/PS vesicles.
Then, the LWB-FFR-fXai•PC/PS complex was titrated with fVa as described above. Finally, the LWB-FFR-fXai•PC/PS•fVa complex was titrated
with prothrombin (closed circles).
were observed in Figure 8A were due to specific protein- respectively [28, 29]. In addition, the availability of anti-
fluorescein antibodies enables this group to double asprotein interactions.
an affinity tag. The bromoacetyl group enables site-spe-
cific conjugation to thiols such as Cys side chains or,Discussion
in this case, a thiol introduced on an irreversible inhibitor.
Several multifunctional reagents have been synthesized,One aim of this study was to monitor the binding of the
enzyme fXa to its substrate prothrombin and to directly and a few are commercially available [30–35]. However,
the advantage of LWB lies in the simplicity of its synthe-measure the effect of fVa on this enzyme•substrate
complex. To this end, we have designed and synthe- sis, the site specificity of its labeling, and its utility as a
detector of effector-induced conformational changes insized LWB, a trifunctional compound (Figure 2) that can
monitor fXa•prothrombin complex formation using two proteins. The compound was synthesized by standard
SPPS using the in situ neutralization/HBTU activationdifferent techniques, namely, fluorescence spectros-
copy and photocrosslinking. procedure for Boc-chemistry.
After synthesis, LWB was incorporated into the activeThe synthesis of LWB was designed to be general for
the production of trifunctional molecules. Because of site of fXa using an approach similar to that of Bock
[23]. Purified fXa was labeled with LWB in the presencethe modular nature of the trifunctional probe, the fluores-
cein can be easily replaced with any other functional of the Bock inhibitor and hydroxylamine. The protein-to-
dye ratio indicates not more than one label per protein.group that can be conjugated to the N terminus of the
probe. If desired, a spacer group could also be inserted Since essentially no labeling of fXa is observed in the
absence of either the Bock reagent or hydroxylamine,between A and B (Figure 2). Next, a functional amino
acid, in this case, a benzoyl phenylalanine, was incorpo- we conclude that LWB attaches specifically to the active
site histidine of fXa via a thioacetyl Phe-Phe-Arg tether.rated. Alternatively, a variety of commercially available
fluorophores or biotinylated amino acids could be sub- The fluorescein moiety in LWB-labeled factor Xa
(LWB-FFR-fXai) had excitation and emission maximastituted. A differentially protected C-terminal Lys resi-
due (Boc-Lys [Fmoc]-OH) enables the reactive conjugat- that were5 nm red shifted compared with fluorescein-
Phe-Phe-Arg-fXai (Fl-FFR-fXai) [36]. However, the emis-ing group to be added in the last step of the synthesis.
In this study, LWB was designed to contain a thiol- sion maximum of LWB-FFR-fXai was very similar to that
observed previously using fluorescein-Glu-Gly-Arg-fXaireactive bromoacetyl group and two equally spaced
functional groups, a photoactivable benzophenone (Fl-EGR-fXai) [36]. The anisotropies of LWB-FFR-fXai
and Fl-FFR-fXai are comparable. These data suggestgroup and a fluorescent fluorescein moiety. The fluores-
cein and benzophenone groups (benzoylphenylalanine) that the addition of the Lys and (benzoyl)-Phe amino
acids to the tripeptide tether does not dramaticallywere chosen for two reasons. First, they can be incorpo-
rated by SPPS, and, second, they provide relatively high change the spectral properties of the fluorescein dye in
Fl-FFR-fXai.quantum yields in fluorescence and photocrosslinking,
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LWB into the active site of fXa did not cause major
changes in the enzyme-lipid interaction [16].
When PC/PS-bound LWB-FFR-fXai was titrated with
fVa, increases in the anisotropy and emission intensity
of the probe were observed. No increase in anisotropy
or intensity was observed when protein C, another mem-
brane binding protein, was added to PC/PS-bound
LWB-FFR-fXai. These data suggest that the LWB probe
specifically detects the fXa-fVa interaction on the phos-
pholipid surface. A 1:1.5 stoichiometry for fXa:fVa was
observed, similar to reports published previously [13,
15, 36, 37]. Since the lifetime of the fluorescein dye is
only4 nsec, time enough to sense only local changes,
Figure 8. LWB as a Photoactivable Probe the fVa-dependent increase in LWB-FFR-fXai anisotropy
(A) LWB-FFR-fXai (50 nM) in 50 mM HEPES (pH 7.4), 150 mM NaCl, suggests an alteration in the local environment of the
2 mM CaCl2 was incubated with 2 M prothrombin and 100 M PC/ dye upon fVa binding. The emission intensity of LWB-
PS vesicles for 5 min at room temperature. The sample was then
FFR-fXai was also sensitive to fVa binding. Because Fl-irradiated with 254 nm UV light as described in the Experimental
FFR-fXai fluorescence intensity does not change signifi-Procedures. The reaction mix was analyzed on a 4%–12% SDS-
PAGE electrophoresis gel. The protein bands were then transferred cantly upon binding fVa [36], LWB-FFR-fXai is a unique
to a membrane and were analyzed by Western blots. The primary probe for monitoring fXa-fVa interactions using fluores-
rabbit polyclonal antibody was directed against human fXa. The cence.
secondary biotin-coupled antibody used here was anti-rabbit IgG. Although one must assume the formation of a
The bands were finally visualized by using streptavidin-coupled al-
fXa•prothrombin complex, i.e., an enzyme•substratekaline phosphatase as described in the Experimental Procedures.
complex, none of the active site fluorescent probes usedLanes 1, 2, 3, and 4 contain the reaction mixture, the reaction per-
formed in the absence of prothrombin, the reaction performed in so far are sensitive to fXa-prothrombin interactions. In
the absence of LWB-FFR-fXai, and prestained molecular weight solid-phase binding assays, fXa appears to bind pro-
standards, respectively. thrombin via the Kringle 2 domain of prothrombin [38].
(B) LWB-FFR-fXai (1 M) in 50 mM HEPES (pH 7.4), 150 mM NaCl, One possible explanation for the inability of active site-
2 mM CaCl2 was incubated with 2 M protein C and 100 M PC/
specific fluorescent probes to sense the fXa-prothrom-PS vesicles (reaction mix) for 5 min at room temperature. The sample
bin interaction could be that the occupancy of the fXawas then irradiated with 254 nm UV light as described in the Experi-
mental Procedures. The sample was then diluted 1000-fold in the active site by these probes blocks the formation of an
reaction buffer, and the reaction mix was analyzed on a 4%–12% enzyme•substrate complex due to steric hindrance.
SDS-PAGE electrophoresis gel. The protein bands were then trans- However, increasing evidence suggests that enzyme-
ferred to a membrane and were analyzed by Western blots. The substrate interactions involving serine proteases in-
primary monoclonal antibody was directed against human protein
volved in blood coagulation are driven by exosite inter-C (C-3). The secondary biotin-coupled antibody used here was anti-
actions that are quite removed from the active site andmouse IgG. The bands were finally visualized by using streptavidin-
coupled alkaline phosphatase as described in the Experimental Pro- that the affinity of the enzyme for its macromolecular
cedures. Lanes 1, 2, 3, and 4 contain the prestained molecular substrate is not affected by the occupancy of the active
weights, the reaction mix without protein C, the reaction mix, and the site by small substrates, inhibitors, and activation pep-
reaction performed in the absence of LWB-FFR-fXai, respectively. tides [19–21]. When LWB-FFR-fXai•PC/PS was titrated
with prothrombin, an initial increase in both the anisot-
ropy and intensity of fluorescein emission that reached
Next, the fluorescein moiety in LWB-FFR-fXai was a plateau at 1.5 M prothrombin (Kd app  816 nM) was
tested for its ability to sense conformational changes observed. This binding curve suggests the formation of
induced in fXa due to lipid and protein interactions. Both an LWB-FFR-fXai•PC/PS•prothrombin ternary complex.
the anisotropy and the emission intensity of LWB-FFR- The concentration of prothrombin in plasma ranges from
fXai were sensitive to phospholipid binding, in contrast 1.1 to 1.7 M, suggesting that this fXa-prothrombin in-
to previous studies in which the fluorescence of Fl-FFR- teraction, though weak, is physiologically relevant [39,
fXai is insensitive to membrane binding [36]. The fluores- 40]. Thus, the development of LWB provides us with
cein dye in Fl-FFR-fXai resides near the S4 pocket of a unique spectroscopic tool to study fXa-prothrombin
fXa. Perhaps moving the spectroscopic probe from the interactions. Additionally, our data provide further evi-
S4 pocket, possibly to the S6 pocket, makes the fluores- dence that a small inhibitor such as LWB-FFR-chloro-
cein more sensitive to the fXa-PC/PS vesicle interaction. methylketone, in the active site of fXa, does not preclude
Alternatively, this increased sensitivity to lipid binding the formation of a LWB-FFR-fXai•PC/PS•prothrombin
could be due to the alteration in the orientation of the complex.
fluorescein dye in the active site region of fXa. The mer- When LWB-FFR-fXai was irradiated with UV light in the
captoacetyl group on the Bock reagent binds to the presence of prothrombin, PC/PS vesicles, and calcium
-amino group end of the Lys on LWB, hence changing ions, high-molecular weight fXa species corresponding
the orientation of the fluorescein moiety in the fXa active to a fXa-prothrombin adduct were generated. This sug-
site compared with Fl-FPR-fXai. The lipid binding titra- gests that prothrombin and fXa were covalently linked
tion curves obtained with LWB-FFR-fXai were similar to in a 1:1 complex after photoactivation of LWB. From
those obtained with a low-quantum yield dansyl-labeled densitometry estimates, 28% of the fXa could be
crosslinked to prothrombin. This relatively high photo-fXa (DEGR-fXai), indicating that the incorporation of
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crosslinking yield may be due to the fact that , mational changes as well as crosslinkink to other pro-
teins, an extended spacer group was not added to-unsaturated ketones react from their UV-excited trip-
let state and the unreacted excited species relax to the extend the crosslinking radius of the benzophenone.
The structure of human active site-inhibited des(1-45)-ground state and may be excited repeatedly until they
react [28]. As a negative control, when LWB-FFR-fXai fXa shows that the active site cleft of fXa is very similar
to that of thrombin [44]. When D-Phe-Pro-Arg-thrombinwas irradiated with UV light in the presence of protein
C, PC/PS vesicles, and calcium ions, no high-molecular was crystallized, the tripeptide inhibitor was observed
to nestle tightly into the active site depression with aweight bands appeared, suggesting the absence of
crosslinks between protein C and fXa. This would sug- third of the inhibitor (D-Phe group) partially exposed
outside the active site groove [45]. LWB is coupled togest that fXa and protein C are not close enough to
each other on vesicles to crosslink, presumably because the active site of fXa via the D-Phe-Phe-Arg inhibitor.
Molecular models of LWB were constructed to estimatethey do not interact with each other. Therefore, the pho-
tocrosslinking data confirm the spectroscopic observa- the crosslinking radius of the molecule. The photoreac-
tive carbonyl in the benzophenone of LWB is approxi-tion that prothrombin and fXa form a specific complex
on negatively charged vesicles even when the fXa active mately 15 A˚ away from the bromoacetyl group on the
Lys. Therefore, from these studies, we estimate thesite is blocked.
The dual functionality of LWB enabled both the anisot- crosslinking radius of the reactive benzophenone in
LWB-FFR-fXai to be 15–20 A˚.ropy and crosslinking studies to be performed on the
same sample. For example, a steady-state fluorescence
experiment at 490 nm yielded fluorescence changes but Significance
no crosslinks; however, when the same sample cuvette
was exposed to 254 nm light after complex formation, Biological processes, such as blood coagulation, oc-
as detected by the anisotropy changes, high-molecular cur in a complex and dynamic environment that is not
weight adducts of prothrombin and fXa could be ob- amenable to structural imaging techniques such as
served on SDS-PAGE (data not shown). These experi- X-ray crystallography and NMR. As a result, tech-
ments demonstrate that both fluorescence and cross- niques such as fluorescence spectroscopy and chemi-
linking experiments can be performed on the same cal crosslinking are useful for obtaining a spatial and
sample using LWB. temporal understanding of multiprotein complex for-
fVa increases kcat and decreases KM for prothrombin mation in these systems, but the results of these ex-
activation by fXa [8, 12]. To determine the effect of fVa on periments can be hard to interpret. During blood coag-
the fXa-prothrombin interaction, preformed LWB-FFR- ulation, a complex is formed between prothrombin,
fXai•PC/PS•fVa ternary complexes were titrated with factor Xa (fXa), and factor Va (fVa), which results in
prothrombin. The prothrombin-dependent increase in cleavage of the proenzyme to its active form, thrombin.
fluorescein anisotropy and intensity reached a plateau Here, the formation of the fXa•fVa•prothrombin com-
value at less than 150 nM of prothrombin. Accounting plex is examined using LWB, a newly developed re-
for the dilution of sample in the cuvette during titration, agent, which was designed to conjugate to thiols in a
a 1:1 stoichiometry for fXa:prothrombin was observed site-specific manner, photocrosslink specific en-
in the presence of fVa (Kd app  15 nM). This suggests zyme•substrate complexes, and allow for the detec-
that the fVa increases 50-fold the affinity of fXa for pro- tion of conformational changes in the active site of
thrombin and that this enhanced affinity does not require enzymes by fluorescence spectroscopy. In this study,
binding of prothrombin to the fXa active site. Thus, our LWB is specifically attached to the active site of fXa
spectroscopic studies are in agreement with the kinetic and is successfully used to monitor the interaction of
data that indicate that the KM for the activation of pro- fXa with different components of the prothrombinase
thrombin by fXa is markedly reduced by fVa. Several complex. Further, the use of LWB shows that the
groups have reported a weak interaction between fVa affinity of fXa for prothrombin increases by 50-fold
and prothrombin [41–43]. However, all of these data are in the presence of fVa and negatively charged phos-
in the absence of phospholipids. Therefore, it is hard pholipids. Together, the experiments described in this
to tell if the fXa-prothrombin and the fVa-prothrombin work and the reagent characterized in this study (LWB)
interactions are synergically enhanced in the prothrom- provide researchers with insight into the formation of
binase complex in the presence of phospholipds. The the prothrombinase complex and a tool with which to
anisotropy changes observed upon titrating prothrom- pursue further studies.
bin into the LWB-FFR-fXai•PC/PS•fVa ternary complex
represent the cumulative sum of changes observed dur-
Experimental Procedures
ing the titration of LWB-FFR-fXai•PC/PS with fVa and
LWB-FFR-fXai•PC/PS with prothrombin. This suggests Materials
the formation of an LWB-FFR-fXai•PC/PS•fVa•pro- Boc-Lys (Fmoc)-OH was purchased from Midwest Biotech. Boc-
p-benzoyl-Phe-OH was obtained from Bachem Biosciences, andthrombin complex. Therefore, in addition to enhancing
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-the membrane binding affinity of fXa, increasing the
phosphate (HBTU) was obtained from Nova Biochem. N, N-diisopro-catalytic efficiency of fXa, and reorienting the active site
pylethylamine (DIEA) was purchased from Applied Biosystems. Tri-of fXa, fVa also increases the inherent affinity of fXa for
fluoroacetic acid (Halocarbon), hydrogen fluoride (HF) gas
prothrombin. (Matheson Gas), and p-methylbenzhydrylamine HCl (MBHA) resin
Because LWB was designed to perform dual func- (Peninsula Laboratories) used in peptide synthesis were purchased
as indicated. N, N	-diisopropylcarbodiimide (DIC), bromoacetictions, such as sensing local environmental and confor-
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acid, and piperidine were obtained from Sigma-Aldrich Research Synthesis of N-([acetylmercapto]acetyl)-(D-Phenylalanyl)-
Phenylalanyl-Arginyl-ChloromethylketoneCompany. 5-carboxyfluorescein and succinimidylacetylthioacetate
N-([acetylmercapto]acetyl)-(D-phenylalanyl)-phenylalanyl-arginyl-were obtained from Molecular Probes. D-phenylalanylphenylalanyl-
chloromethylketone (AMA-FFR-CK, Bock reagent) was synthesizedarginyl chloromethylketone was purchased from Calbiochem. Dio-
and purified [23]. (D-phenylalanyl)-phenylalanyl-arginyl-chlorometh-leoylphosphatidylcholine (PC) and dioleoylphosphatidylserine (PS)
ylketone (8.7 mM) in 50 mM Na2HPO4 (pH 7.0) was incubated withwere obtained from Avanti Polar Lipids. L-3-phosphatidylcholine-
succinimidylacetylthioacetate (47 mM) in methanol for 30 min. The1,2-di[1-14C]oleoyl ([14C]PC) was purchased from Amersham Phar-
reaction mix was then diluted 5-fold with 25 mM NaH2PO4 (pH 3.0),macia Biotech. N-benzoylisoleucylglutamylglycylarginyl-p-nitroani-
and the pH was adjusted to 3.0 with o-phosphoric acid. The productline (S2222) was obtained from DiaPharma.
was purified from the reactants on a Rainin HPLC system using a
semipreparative reverse phase Vydac C-18 column (10 m, 1.0 

25 cm). Linear gradients of acetonitrile in water/0.1% TFA were usedProteins
to elute the AMA-FFR-CK from the column. The synthesis of theHuman fXa was activated from human fX using Russell’s viper
product was confirmed by ESI-MS. The concentration of AMA-FFR-venom (RVV-X, Enzyme Research Laboratories) and was purified
CK was determined by a colorimetric assay using 5, 5	-dithio bis-from the reactants according to previously described procedures
(2-nitrobenzoic acid) (DTNB) as described by Bock [23].[46]. Human -thrombin, factor VIIa, and fXa (for some experiments)
were obtained from Enzyme Research Laboratories. fVa was pur-
Active Site-Directed Labeling of Factor Xa with LWBchased from Haematologic Technologies.
Following the activation and purification of factor Xa from zymogenPolyclonal rabbit anti-human fX was obtained from Celsus Labo-
factor X and RVV-X, factor Xa (5 mg) was incubated at room temper-ratories. Enzyme-linked immunosorbent assay kits for fXa were ob-
ature with a 5-fold molar excess of AMA-FFR-CK in 5 ml of 50 mMtained from Affinity Biologicals. Monoclonal anti-human protein C
HEPES (pH 7.4), 150 mM NaCl, plus 2 mM CaCl2 (buffer A) [23]. The(C-3) was prepared according to procedures published earlier [47].
extent of active site labeling was monitored by the loss of enzymaticBiotin-labeled secondary antibody, alkaline phosphatase-conju-
activity of factor Xa using a chromogenic substrate S2222 untilgated streptavidin, 5-bromo-4-chloro-3	-indolyphosphate-p-tolu-
factor Xa was 99.9% inactive. The inactivated factor Xa (AMA-idine chloride (BCIP), and nitro-blue-tetrazolium chloride (NBT) sub-
FFR-fXai) was dialyzed against 1 liter of buffer A at 4C with twostrate were purchased from Pierce.
changes to remove unreacted reagent. The resulting preparation
was treated with a 5-fold molar excess of LWB in DMF (final concen-
tration of 5% in solution) in the presence of 0.1 M hydroxylamineSynthesis of LWB
for 1 hr at 25C in the dark. Finally, LWB-mercaptoacetyl-Phe-Phe-LWB (N-fluorescein-p benzoyl phenylalanyl-lysyl [N bromoacetyl]
Arg-factor Xa (LWB-FFR-fXai) was purified from the excess of unre-amide, Figure 2) was synthesized by manual solid-phase peptide
acted reagents by initially passing the reaction mix over a Microconsynthesis, typically on a 0.2-mmol scale using the in situ neutraliza-
centrifugal device (30-kDa cutoff; Millipore), followed by extensivetion/HBTU activation procedure for Boc-chemistry [22]. After the
dialysis against buffer A (2000 ml 
 3 changes) at 4C in the dark.neutralization of the MBHA resin with DIEA (2 
 10% in DMF for 2
LWB-FFR-fXai was aliquoted, quick frozen, and stored at 80C.min), the Boc-Lys (Fmoc)-OH (0.44 mmol) was activated with 0.4
mmol (800 l) HBTU and 200 l DIEA and was coupled to the resin
Preparation of Phospholipid Vesiclesfor 30 min. A quantitative ninhydrin test was performed to determine
Small unilamellar vesicles of phosphatidylcholine/phosphatidylser-the extent of coupling [48]. After 99% of the lysine was coupled
ine (PC/PS, 4:1 mole ratio) were prepared using sonication andto the resin, the excess uncoupled lysine was then washed away
centrifugation procedures as described [15]. Lipid recovery post-with three flow washes of DMF.
centrifugation was quantified using a trace amount of [14C]phospha-Next, for the coupling of Boc-p-benzoyl-Phe-OH, the N-Boc pro-
tidylcholine in the sonication mixture [15].tecting group on Boc-Lys (Fmoc)-OH was removed from the fully
protected peptide-resin by two 1-min washes with TFA, and the
Spectral Measurementsresin was washed with DMF. The phenylalanyl derivative was acti-
Steady-state fluorescence intensity and anisotropy measurementsvated with HBTU as described above and was coupled to Lys
were made using a SLM 8100 photon-counting spectrofluorometer(Fmoc)-MBHA resin (30 min, 99%). The peptide resin was washed
or a SLM AB2 Luminescence spectrometer (SLM Aminco) equippedwith DMF and was neutralized with 10% DIEA. The 5-carboxyfluo-
with a 450-W xenon arc lamp, two holographic gratings in the excita-
rescein dye (0.75 mmol) was activated with 0.25 mmol DIC in CH2Cl2 tion light path, and an IBM computer for data analysis. Fluorescein
(15 min on ice) and was coupled to the peptide resin. The reaction
fluorescence was detected at its emission and excitation maxima
was allowed to proceed until 99% of the fluorescein was coupled
wavelengths. A circulating water bath was used to maintain the
to the resin.
sample compartment at 25C. All fluorescence experiments were
The Fmoc group on the Lys residue was removed by treatment performed in 5 mm 
 5 mm quartz cuvettes using a 345-nm cutoff
with 20% piperidine in DMF for 5–10 min. Then, 2-bromoacetic acid filter (Schott Glass) in the excitation beam path. Samples were mixed
(2 mmol) in 500 l CH2Cl2 was activated with 1 mmol DIC (15 min using a small teflon-coated 2 mm 
 2 mm magnetic spinbar as
on ice). The resulting symmetric anhydride was added to the resin described before [49]. Absorption of protein to the cuvette walls
and was coupled for 15 min. This procedure bromoacetylates the was minimized by coating the cuvettes with 100% PC vesicles as
-amino group of the Lys on the peptide. described [50].
The fluorescein-labeled peptide was then simultaneously cleaved For a typical fluorescence experiment, two samples were pre-
from the resin and was deprotected by treatment with anhydrous pared in parallel. The sample cuvette (S) received 200 nM LWB-
HF for 1 hr at 0C with 4% p-cresol as a scavenger. After cleavage, FFR-fXai in 50 mM HEPES (pH 7.4), 150 mM NaCl, and 2 mM CaCl2,
the peptide was precipitated and washed with ice-cold diethylether, whereas the blank cuvette (B) received 200 nM FFR-fXai in the same
dissolved in 50% acetic acid, filtered, and lyophilized. Finally, LWB buffer. The initial net fluorescence intensity of the sample, desig-
was redissolved in 30% buffer B containing 2, 2, 2-trifluoroethanol nated Fo, was obtained by the subtraction of a dye-free blank from
and was purified from p-cresol and other reaction side products by the S cuvette signal. For the phospholipid titrations, small unilamel-
semipreparative reverse phase HPLC on a Rainin HPLC system lar vesicles of PC/PS were added to each cuvette. After the signal
using a Vydac C-18 column (10 m, 1.0 
 25 cm). Linear gradients observed in the absence of the dye (sample B) was subtracted from
of acetonitrile in water/0.1% TFA were used to elute the bound that in the presence of the dye (Sample S), the net volume-corrected
peptide. Dual wavelength detection at 214 and 480 nm was em- signal was designated F at that point in the titration. Protein titrations
ployed to monitor the elution of the fluorescent peptide from the were performed in the presence of saturating phospholipids analo-
column. The product was confirmed by ESI-MS analysis. The theo- gously.
retical mass of the compound was calculated using ChemDraw Pro Steady-state anisotropy was measured using Glan-Thompson
prism polarizers on both the excitation and emission beams. The6.0 version software (Cambridge Soft).
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